-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Enanta Pharmaceuticals, Lowers Price Target to $17

Benzinga·11/20/2026 17:55:12
Listen to the news
JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.